OrbiMed Advisors LLC, OrbiMed Asia GP II, L.P., and OrbiMed Advisors II Limited have filed an amendment with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024, indicating a decrease in their beneficial ownership of Apollomics Inc. shares by more than 1% due to an increase in the number of shares outstanding. The filing, known as Amendment No. 5 to Schedule 13D, updates previous statements regarding their holdings in Apollomics, a biopharmaceutical company with Class A ordinary shares listed on the Nasdaq under the ticker APLM. The Reporting Persons now collectively hold approximately 7.9% of the issued and outstanding Class A Ordinary Shares, including shares that may be acquired through exercisable warrants. The amendment follows a series of previous filings dating back...Show More

OrbiMed Advisors LLC, OrbiMed Asia GP II, L.P., and OrbiMed Advisors II Limited have filed an amendment with the U.S. Securities and Exchange Commission (SEC) on May 20, 2024, indicating a decrease in their beneficial ownership of Apollomics Inc. shares by more than 1% due to an increase in the number of shares outstanding. The filing, known as Amendment No. 5 to Schedule 13D, updates previous statements regarding their holdings in Apollomics, a biopharmaceutical company with Class A ordinary shares listed on the Nasdaq under the ticker APLM. The Reporting Persons now collectively hold approximately 7.9% of the issued and outstanding Class A Ordinary Shares, including shares that may be acquired through exercisable warrants. The amendment follows a series of previous filings dating back to April 12, 2023. OrbiMed Advisors, a Delaware limited liability company and registered investment adviser, along with the other Reporting Persons, have shared voting and dispositive power over the shares held by OrbiMed Asia Partners II, L.P. The Reporting Persons have expressed that they may review their investment and make future changes based on various factors, including market conditions and the company's performance.